RFA-TR-21-001: New Chemistries for Un-drugged Targets through A Specialized Platform for Innovative Research Exploration (ASPIRE) Collaborative Research Program (UG3/UH3 Clinical Trials Not Allowed)
Internal Deadline: March 12, 2021, 5pm PT
LOI: June 8, 2021
External Deadline: July 8, 2021, 5pm local time
Award Type: Cooperative Agreement
Estimated Number of Awards: 2
Anticipated Amount: $4,000,000 in FY 2021
Process for Limited Submissions: PIs must submit their application as a Limited Submission through the Office of Research Application Portal: https://research.usc.edu/usc-grants/. For all competitions mentioned in the digest, select the ‘Limited Submission’ option at the top to submit.
Materials to submit include:
(1) Single Page Proposal Summary (0.5” margins; single-spaced; font type: Arial, Helvetica, or Georgia typeface; font size: 11 pt). Page limit includes references and illustrations. Pages that exceed the 1-page limit will be excluded from review.
(2) CV – (5 pages maximum)
Who May Serve as PI: This program requires the full collaboration of the extramural PD/PI of the applicant institution and the intramural investigator(s). Accordingly, the Multiple PD/PI model is allowed, but not required. For those applicants opting not to use the Multiple PD/PI model, the intramural investigator can hold any role other than the multiple PD/PI role. Applications must include at least one intramural scientist as either a Program Director/Principal Investigator or collaborator.
Purpose: The purpose of the ASPIRE Collaborative Research Program is to facilitate translational and clinical research between NCATS intramural scientists and the extramural community to develop approaches that will enhance the ability to discover and develop new chemistries towards previously undrugged biological targets (i.e., biological targets with no known drugs to modulate their function) across many human diseases and conditions. NCATS intramural scientists have established an integrated NCATS ASPIRE platform consisting of physical and virtual modules for automated synthetic chemistry, artificial intelligence (AI) and machine learning (ML), engineering, informatics, and biological testing. The FOA will support intramural – extramural collaborations to develop additional physical modules that will enhance the platform’s capabilities. The anticipated outcome includes identification, design, synthesis, and validation of new chemical entities as starting points for drug development of novel targets, and the expansion of chemical space available for drug screening.
Budgetary Requirements: This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.
Visit our Institutionally Limited Submission webpage for more updates and other announcements.